Healthcare provider profile · identity verified

Chadwick Michael Kemp, NP-C

Nurse Practitioner · MADISON, AL · NPI 1871102822

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Levothyroxine Sodium	Levothyroxine Sodium	450	77
Amlodipine Besylate	Amlodipine Besylate	289	44
Atorvastatin Calcium	Atorvastatin Calcium	234	37
Pantoprazole Sodium	Pantoprazole Sodium	232	41
Furosemide	Furosemide	231	61
Losartan Potassium	Losartan Potassium	217	34
Donepezil Hcl	Donepezil Hcl	212	34
Lisinopril	Lisinopril	194	26
Omeprazole	Omeprazole	172	28
Sertraline Hcl	Sertraline Hcl	158	23
Simvastatin	Simvastatin	151	17
Metoprolol Succinate	Metoprolol Succinate	139	22
Eliquis	Apixaban	133	29
Memantine Hcl	Memantine Hcl	130	22
Buspirone Hcl	Buspirone Hcl	129	24
Tamsulosin Hcl	Tamsulosin Hcl	128	19
Carvedilol	Carvedilol	122	20
Potassium Chloride	Potassium Chloride	121	26
Mirtazapine	Mirtazapine	120	19
Nitrofurantoin Mono-Macro	Nitrofurantoin Monohyd/M-Cryst	119	69
Famotidine	Famotidine	115	20
Escitalopram Oxalate	Escitalopram Oxalate	100	12
Duloxetine Hcl	Duloxetine Hcl	99	14
Metformin Hcl	Metformin Hcl	96	suppressed
Pravastatin Sodium	Pravastatin Sodium	93	16
Torsemide	Torsemide	93	22
Meloxicam	Meloxicam	91	17
Metoprolol Tartrate	Metoprolol Tartrate	89	15
Quetiapine Fumarate	Quetiapine Fumarate	87	15
Clopidogrel	Clopidogrel Bisulfate	82	14
Rosuvastatin Calcium	Rosuvastatin Calcium	78	13
Trazodone Hcl	Trazodone Hcl	77	19
Allopurinol	Allopurinol	76	12
Citalopram Hbr	Citalopram Hydrobromide	73	12
Fluticasone Propionate	Fluticasone Propionate	65	20
Oxcarbazepine	Oxcarbazepine	65	suppressed
Loperamide	Loperamide Hcl	61	48
Spironolactone	Spironolactone	61	suppressed
Latanoprost	Latanoprost	56	suppressed
Hydrochlorothiazide	Hydrochlorothiazide	51	suppressed
Nitrofurantoin	Nitrofurantoin Macrocrystal	50	suppressed
Fluoxetine Hcl	Fluoxetine Hcl	45	suppressed
Sucralfate	Sucralfate	43	suppressed
Levetiracetam	Levetiracetam	42	suppressed
Finasteride	Finasteride	41	suppressed
Januvia	Sitagliptin Phosphate	40	suppressed
Ondansetron Hcl	Ondansetron Hcl	37	17
Divalproex Sodium	Divalproex Sodium	36	suppressed
Hydralazine Hcl	Hydralazine Hcl	36	suppressed
Oxybutynin Chloride	Oxybutynin Chloride	35	suppressed
Venlafaxine Hcl	Venlafaxine Hcl	35	suppressed
Carbidopa-Levodopa	Carbidopa/Levodopa	33	suppressed
Cephalexin	Cephalexin	33	28
Oxybutynin Chloride Er	Oxybutynin Chloride	33	suppressed
Alendronate Sodium	Alendronate Sodium	32	suppressed
Telmisartan	Telmisartan	30	suppressed
Jardiance	Empagliflozin	29	suppressed
Bupropion Xl	Bupropion Hcl	28	suppressed
Ciprofloxacin Hcl	Ciprofloxacin Hcl	28	23
Myrbetriq	Mirabegron	27	suppressed
Triamcinolone Acetonide	Triamcinolone Acetonide	27	22
Valsartan	Valsartan	27	suppressed
Venlafaxine Hcl Er	Venlafaxine Hcl	27	suppressed
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	26	suppressed
Calcitriol	Calcitriol	25	suppressed
Paroxetine Hcl	Paroxetine Hcl	25	suppressed
Lamotrigine	Lamotrigine	24	suppressed
Amiodarone Hcl	Amiodarone Hcl	23	suppressed
Irbesartan	Irbesartan	23	suppressed
Nystatin	Nystatin	23	19
Solifenacin Succinate	Solifenacin Succinate	23	suppressed
Azithromycin	Azithromycin	22	20
Risperidone	Risperidone	22	suppressed
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	21	suppressed
Montelukast Sodium	Montelukast Sodium	21	suppressed
Ezetimibe	Ezetimibe	19	suppressed
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	19	suppressed
Metformin Hcl Er	Metformin Hcl	19	suppressed
Albuterol Sulfate Hfa	Albuterol Sulfate	18	11
Cholestyramine	Cholestyramine (With Sugar)	18	suppressed
Trelegy Ellipta	Fluticasone/Umeclidin/Vilanter	18	suppressed
Autoshield Duo Pen Needle	Pen Needle,dual Safety,diabetc	17	suppressed
Azelastine Hcl	Azelastine Hcl	17	suppressed
Breo Ellipta	Fluticasone/Vilanterol	17	suppressed
Xarelto	Rivaroxaban	17	suppressed
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	16	16
Hydrocortisone	Hydrocortisone	16	suppressed
Rivastigmine	Rivastigmine	16	suppressed
Sulfamethoxazole-Trimethoprim	Sulfamethoxazole/Trimethoprim	15	12
Amitriptyline Hcl	Amitriptyline Hcl	14	suppressed
Butalbital-Acetaminophen	Butalbital/Acetaminophen	14	suppressed
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	14	suppressed
Diltiazem Hcl	Diltiazem Hcl	14	suppressed
Divalproex Sodium Er	Divalproex Sodium	14	suppressed
Farxiga	Dapagliflozin Propanediol	14	suppressed
Memantine Hcl Er	Memantine Hcl	14	suppressed
Cinacalcet Hcl	Cinacalcet Hcl	13	suppressed
Clonidine	Clonidine	13	suppressed
Entresto	Sacubitril/Valsartan	13	suppressed
Lovastatin	Lovastatin	13	suppressed
Methotrexate	Methotrexate Sodium	13	suppressed
Rivastigmine	Rivastigmine Tartrate	13	suppressed
Timolol Maleate	Timolol Maleate	13	suppressed
Tradjenta	Linagliptin	13	suppressed
Acyclovir	Acyclovir	12	suppressed
Diclofenac Potassium	Diclofenac Potassium	12	suppressed
Esomeprazole Magnesium	Esomeprazole Magnesium	12	suppressed
Fluconazole	Fluconazole	12	suppressed
Glipizide	Glipizide	12	suppressed
Lansoprazole	Lansoprazole	12	suppressed
Paroxetine Er	Paroxetine Hcl	12	suppressed
Constulose	Lactulose	11	suppressed
Isosorbide Mononitrate Er	Isosorbide Mononitrate	11	suppressed
Levocetirizine Dihydrochloride	Levocetirizine Dihydrochloride	11	suppressed
Prednisone	Prednisone	11	suppressed
Verapamil Er	Verapamil Hcl	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error